DUKE UNIVERSITY Patent applications |
Patent application number | Title | Published |
20160129282 | SYSTEMS AND METHODS FOR SPECIFYING TREATMENT CRITERIA AND TREATMENT PARAMETERS FOR PATIENT SPECIFIC RADIATION THERAPY PLANNING - Disclosed herein are systems and methods for specifying treatment criteria and treatment planning parameters for patient specific radiation therapy planning. According to an aspect, a method includes receiving data about a patient, computing geometric characterization of one or more organs at risk proximate to a target volume of a patient or vice versa, and selecting relevant treatment knowledge and experience. The method also includes generating, based on the received data, computed geometric characterization, and available knowledge and experience, a first set of radiation treatment planning parameters that will lead to a high quality plan for the patient. Further, the method includes model-based prediction, based on the data, a second set or more of radiation treatment planning parameters that will lead to alternative achievable plans with different organ sparing objectives for treating the patient. The multiple sets for parameters can be used separately or in conjunction to generate treatment plans. | 05-12-2016 |
20160114320 | Droplet Manipulation Device - Methods are provided for manipulating droplets. The methods include providing the droplet on a surface comprising an array of electrodes and a substantially co-planer array of reference elements, wherein the droplet is disposed on a first one of the electrodes, and the droplet at least partially overlaps a second one of the electrodes and an intervening one of the reference elements disposed between the first and second electrodes. The methods further include activating the first and second electrodes to spread at least a portion of the droplet across the second electrode and deactivating the first electrode to move the droplet from the first electrode to the second electrode. | 04-28-2016 |
20160081858 | Compositions and Methods for the Prevention of Scarring and/or Promotion of Wound Healing - The present disclosure provides methods of preventing and/or reducing scar contracture and methods of promoting wound healing by utilizing an electrospun biocompatible scaffold. | 03-24-2016 |
20160032007 | Human Antibody Fragments Against Chondroitin Sulfate Proteoglycan 4 (CSPG4) - Human antibody fragments against chrondroitin sulfate proteoglycan 4 can be used to deliver cytotoxic agents to cells which express CSPG4. The agents can be diagnostic or therapeutic moieties. They may be linked by covalent or non-covalent linkages to the antibody fragments. They may be produced as a genetic fusion product or joined together synthetically, for example. When the human antibody fragments are internalized by the cells to which they bind, they can carry with them the attached agents. Thus toxic agents having intracellular targets have enhanced killing upon internalization. | 02-04-2016 |
20160030332 | 2-FLUORO-MODIFIED RNAs AS IMMUNOSTIMULATORS - Methods of inhibiting the growth of cells or inducing cell death by contacting the cells with or introducing into the cells a composition including a 5′ triphosphate, 2′ fluoro-modified pyrimidine non-linear single stranded RNA at least 17 nucleotides long with a least 3 base pairings or a 5′ triphosphate, 2′ fluoro-modified double stranded RNA at least 17 base pairs long in an amount effective to inhibit cell growth, induce cell death or induce cytokine production by the cells. The methods also include administration of the compositions to a subject. The subject may have a proliferative disorder or infectious disease and administration of the compositions provided herein may treat the disorder or disease. | 02-04-2016 |
20160024585 | METHODS OF PREDICTING RESPONSIVENESS OF A CANCER TO AN AGENT AND METHODS OF DETERMINING A PROGNOSIS FOR A CANCER PATIENT - The present disclosure provides biomarkers, and methods of using such biomarkers, that are predictive for efficacy of and resistance to an EGFR targeting agent, such as cetuximab, or prognostic with respect to cancer survival. | 01-28-2016 |
20160016172 | Droplet-Based Nucleic Acid Amplification Method and Apparatus - Aspects of embodiments of the invention relate to a simulator including a visual display capable of outputting to a user a display one or more effects of a command series selected and a system including a droplet microactuator electronically coupled to and controlled by a processor capable of executing instructions, the droplet microactuator including a substrate comprising electrodes for conducting droplet operations. Further aspects of embodiments of the invention relate to a droplet operations troubleshooting apparatus. Other aspects of embodiments of the invention relate to a computer implemented method of displaying simulated microactuator droplets. | 01-21-2016 |
20160005503 | PLASMONIC ASSISTED SYSTEMS AND METHODS FOR INTERIOR ENERGY-ACTIVATION FROM AN EXTERIOR SOURCE - A method and a system for producing a change in a medium disposed in an artificial container. The method places in a vicinity of the medium at least one of a plasmonics agent and an energy modulation agent. The method applies an initiation energy through the artificial container to the medium. The initiation energy interacts with the plasmonics agent or the energy modulation agent to directly or indirectly produce the change in the medium. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the plasmonics agent or the energy modulation agent. | 01-07-2016 |
20150336098 | Apparatuses and Methods for Manipulating Droplets - Apparatuses and methods for manipulating droplets are disclosed. In one embodiment, an apparatus for manipulating droplets is provided, the apparatus including a substrate, multiple arrays of electrodes disposed on the substrate, wherein corresponding electrodes in each array are connected to a common electrical signal, and a dielectric layer disposed on the substrate first side surface and patterned to cover the electrodes. | 11-26-2015 |
20150335732 | COMPOSITIONS, METHODS, AND KITS FOR ELICITING AN IMMUNE RESPONSE - The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided. | 11-26-2015 |
20150329497 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 - Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds. | 11-19-2015 |
20150323496 | Integrated Droplet Actuator for Gel Electrophoresis and Molecular Analysis - The invention is directed to a droplet actuator device and methods for integrating gel electrophoresis analysis with pre or post-analytical sample handling as well as other molecular analysis processes. Using digital microfluidics technology, the droplet actuator device and methods of the invention provide the ability to perform gel electrophoresis and liquid handling operations on a single integrated device. The integrated liquid handling operations may be used to prepare and deliver samples to the electrophoresis gel, capture and subsequently process products of the electrophoresis gel or perform additional assays on the same sample materials which are analyzed by gel electrophoresis. In one embodiment, one or more molecular assays, such as nucleic acid (e.g., DNA) quantification by real-time PCR, and one or more sample processing operations such as sample dilution is performed on a droplet actuator integrated with an electrophoresis gel. In one embodiment, an electrophoresis gel may be integrated on the top substrate of the droplet actuator. | 11-12-2015 |
20150316605 | SOFTWARE-BASED SELF-TEST AND DIAGNOSIS USING ON-CHIP MEMORY - Embedded processor-based self-test and diagnosis using the compressed test data is described for ICs having on-chip memory. Techniques for compressing the test data before the compressed test data is transferred to a device under test (DUT) are also described. A modified LZ77 algorithm can be used to compress strings of test data in which don't care bits are handled by assigning a value to the don't care bits according to a longest match in the window as the data is being encoded. The compressed test data can be decompressed at the DUT using a software program transferred by the automated test equipment (ATE) to the DUT with the compressed test data. Decompression and diagnostics can be carried out at the DUT using an embedded processor and the on-chip memory. Results from the diagnostics can be read by the ATE. | 11-05-2015 |
20150305717 | METHODS, SYSTEMS AND COMPUTER PROGRAM PRODUCTS FOR MULTI-RESOLUTION IMAGING AND ANALYSIS - Methods for determining a mechanical parameter for a sample having a target region include generating a tissue displacement in the target region; transmitting tracking pulses in the target region; receiving corresponding echo signals for the tracking pulses in the target region at a plurality of positions; analyzing the echo signals at one or more multi-resolution pairs of the positions and/or acquisition times; and determining at least one mechanical parameter of the target region based on the echo signals at the one or more multi-resolution pairs of positions and/or acquisition times. | 10-29-2015 |
20150283392 | UP AND DOWN CONVERSION SYSTEMS FOR PRODUCTION OF EMITTED LIGHT FROM VARIOUS ENERGY SOURCES INCLUDING RADIO FREQUENCY, MICROWAVE ENERGY AND MAGNETIC INDUCTION SOURCES FOR UPCONVERSION - Methods and systems for producing a change in a medium. A first method and system (1) place in a vicinity of the medium at least one upconverter including a gas for plasma ignition, with the upconverter being configured, upon exposure to initiation energy, to generate light for emission into the medium, and (2) apply the initiation energy from an energy source including the first wavelength λ | 10-08-2015 |
20150281910 | UNSUPERVISED INDOOR LOCALIZATION AND HEADING DIRECTIONS ESTIMATION - Systems and methods for unsupervised indoor localization are provided. Sensor data obtained from a device carried by a user can be used to simultaneously estimate the indoor location of a user and identify landmarks within the indoor environment based on their signatures. The landmarks can be used to reset the location estimate of the user, and the location estimate of the user can be used to improve the learned location of the landmarks. This recursive process leads to excellent accuracy in indoor localization. Systems and methods for estimating the heading direction of a user are also provided. Sensor data obtained from the user can be used to analyze the forces acting on the user in order to give an accurate heading direction estimate. | 10-01-2015 |
20150265706 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS USING PLASMONICS ENHANCED PHOTOSPECTRAL THERAPY (PEPST) AND EXCITON-PLASMON ENHANCED PHOTOTHERAPY (EPEP) - The use of plasmonics enhanced photospectral therapy (PEPST) and exiton-plasmon enhanced phototherapy (EPEP) in the treatment of various cell proliferation disorders, and the PEPST and EPEP agents and probes used therein. | 09-24-2015 |
20150265684 | METHODS OF TREATING HEMOGLOBINOPATHIES - Methods of alleviating the symptoms of hemoglobinopathies, including, but not limited to, sickle cell disease, β-thalassemia, and hemoglobin H disease are provided. In some embodiments, the methods comprise administering an inhibitor selected from a β-arrestin1/2 inhibitor and/or a GRK2 inhibitor to the subject. Methods of inhibiting adhesion of sickle red blood cells to endothelial cells and adhesion to and activation of leukocytes are also provided. | 09-24-2015 |
20150265245 | pMUT ARRAY FOR ULTRASONIC IMAGING, AND RELATED APPARATUSES, SYSTEMS, AND METHODS - Piezoelectric Micromachined Ultrasound Transducer (pMUT) arrays for ultrasonic imaging, and related apparatuses, systems, and methods are disclosed. In one embodiment, an ultrasonic imaging assembly comprises a substrate and a plurality of array elements arranged on the substrate in an array. Each array element comprises at least one pMUT disposed on the substrate each having a geometry configured to accept a predetermined fundamental mode vibration. The plurality of array elements are configured to transmit and receive at least one ultrasound beam based on the predetermined fundamental mode vibration. By sizing the pMUTs to correspond to a desired fundamental mode vibration, the pMUT array has improved sensitivity, and can be produced relatively cheaply compared to conventional dicing methods. | 09-24-2015 |
20150251016 | NON-INVASIVE ENERGY UPCONVERSION METHODS AND SYSTEMS - Products, compositions, systems, and methods for modifying a target structure. The methods may be performed in a non-invasive manner by placing a nanoparticle having a metallic shell on at least a fraction of a surface in a vicinity of a target structure in a subject and applying an initiation energy thus producing an effect on or change to the target structure directly or via a modulation agent. The nanoparticle is configured, upon exposure to a first wavelength λ | 09-10-2015 |
20150246521 | ADHESIVE BONDING COMPOSITION AND METHOD OF USE - A polymerizable composition includes at least one monomer, a photoinitiator capable of initiating polymerization of the monomer when exposed to light, and a phosphor capable of producing light when exposed to radiation (typically X-rays). The material is particularly suitable for bonding components at ambient temperature in situations where the bond joint is not accessible to an external light source. An associated method includes: placing a polymerizable adhesive composition, including a photoinitiator and energy converting material, such as a down-converting phosphor, in contact with at least two components to be bonded to form an assembly; and, irradiating the assembly with radiation at a first wavelength, capable of conversion (down-conversion by the phosphor) to a second wavelength capable of activating the photoinitiator, to prepare items such as inkjet cartridges, wafer-to-wafer assemblies, semiconductors, integrated circuits, and the like. | 09-03-2015 |
20150229133 | SUBSCRIPTION BASED MISO AND MIMO WIRELESS ENERGY TRANSFER - Subscription based multiple-in-put-single-output and multiple-input-multiple-output wireless energy transfer enables selective charging and powering of mobile devices using a plurality of spatially distributed transmitters that are synchronized under the control of a transmitter controller. Amplitude, phase, and frequency of each transmitter is controlled to promote or deny the transfer of energy to particular mobile devices or positions through optimization techniques based on the incident power level at each mobile device subscribing to the system. Measurements related to the incident power level may be directly provided by the mobile device or the incident power is remotely determined through analysis of backscatter gains. | 08-13-2015 |
20150216416 | System and Method for Large Field of View, Single Cell Analysis - A method and system for medical imaging employs an excitation source configured to cause an object having a plurality of cells to at least one of emit, reflect, and fluoresce light. An optical receptor is employed that is configured to receive the light from the object. A filter assembly receives the light from the optical receptor and filters the light. An image processor having a field of view (FOV) substantially greater than a diameter of a cell of the object and an analysis resolution substantially matched to the diameter of a cell of the object that receives the filtered light from the filter and analyzes the filtered light corresponding to each cell in the FOV. A feedback system is provided that is configured to provide an indication of a state of each cell in the FOV and a location of a cell in the FOV meeting a predetermined condition. | 08-06-2015 |
20150202294 | USE OF PSORALEN DERIVATIVES AND COMBINATION THERAPY FOR TREATMENT OF CELL PROLIFERATION DISORDERS - Methods for the treatment of a cell proliferation disease or disorder in a subject, involving applying a psoralen derivative lacking a DNA cross-linking motif to cancer cells, applying a psoralen or a derivative thereof and lapatinib, or applying a psoralen or derivative thereof and neratinib, to a subject and further applying initiation radiation energy form an energy source. | 07-23-2015 |
20150191471 | COMPOUNDS AND METHODS FOR TARGETING HSP90 - Described herein are compounds that may selectively bind to Hsp90, methods of using the compounds, and kits including the compounds. The compounds may include detection moieties such as fluorophores that may allow for selective detection of Hsp90 in a sample. | 07-09-2015 |
20150174577 | Filler Fluids for Droplet Operations - The present invention relates to filler fluids for droplet operations. According to one embodiment of this aspect, a droplet microactuator is provided and includes: (a) a first substrate comprising electrodes configured for conducting droplet operations on a surface of the substrate; (b) a second substrate spaced from the surface of the substrate by a distance sufficient to define an interior volume between the first substrate and second substrate, wherein the distance is sufficient to contain a droplet disposed in the space on the first substrate; and (c) a droplet arranged in the interior volume and arranged with respect to the electrodes in a manner which permits droplet operations to be effected on the droplet using the electrodes. | 06-25-2015 |
20150154741 | MULTI-SHOT SCAN PROTOCOLS FOR HIGH-RESOLUTION MRI INCORPORATING MULTIPLEXED SENSITIVITY-ENCODING (MUSE) - Multi-shot DWI with multiplexed sensitivity-encoding (MUSE) inherently corrects nonlinear shot-to-shot phase variations without requiring the use of navigator echoes. The multi-shot DWI can use interleaved echo-planar imaging or other scan protocols. This new technique should prove highly valuable for mapping brain structures and connectivities at high spatial resolution for neuroscience studies. | 06-04-2015 |
20150132760 | METHODS OF DETECTING CHARCOT-MARIE TOOTH DISEASE TYPE 2A - Methods are described for screening a subject for risk of Charcot-Marie-Tooth Disease Type 2A or for diagnosing Charcot-Marie-Tooth disease or a predisposition for developing Charcot-Marie-Tooth disease in a subject, by detecting the presence or absence of a mutation in the mitofusin gene in a biological sample collected from the subject. Methods are also described for detecting the presence of a genetic polymorphism associated with Charcot-Marie-Tooth Disease Type 2A in a sample of patient nucleic acid, by amplifying a mitofusin gene sequence in the patient nucleic acid to produce an amplification product; and identifying the presence of a Charcot-Marie-Tooth Disease Type 2A associated polymorphism in the amplification product. | 05-14-2015 |
20150118181 | Concurrent Chemotherapy and Immunotherapy - The concurrent administration of chemotherapy and immunotherapy has been considered a contraindication because of the concern that the induced lymphopenia would ablate therapeutic efficacy of immunotherapy. Temozolomide has been shown to be an effective chemotherapeutic for patients with malignant gliomas and to deprive patients with glioblastoma (GBM) patients of this agent in order to treat with immunotherapy is controversial. Despite conventional dogma, we demonstrate that both chemotherapy and immunotherapy can be delivered concurrently without negating the effects of immunotherapy. In fact, the temozolomide induced lymphopenia may actually be synergistic with a peptide vaccine. | 04-30-2015 |
20150105345 | USES OF ANTAGONISTS OF HYALURONAN SIGNALING - Described herein is the finding that hyaluronan antagonists that inhibit hyaluronan signaling are capable of inhibiting airway inflammation and airway hyperresponsiveness (AHR). The present disclosure provides a method of preventing or reducing AHR in a subject suffering from or at risk for AHR by administering a hyaluronan antagonist. Also provided is a method of treating an airway disease or disorder in a subject by administering a hyaluronan antagonist. Hyaluronan antagonists include, for example, heparosan and hyaluronan oligosaccharides (oHAs). In some embodiments, the hyaluronan antagonist is administered locally to the airway, such as with an inhaler or nebulizer. | 04-16-2015 |
20150083923 | LINEAR-RESPONSE NANOCRYSTAL SCINTILLATORS AND METHODS OF USING THE SAME - Systems and devices incorporating radiation detection, and techniques and materials for improved radiation detection are provided that involve a nano-scintillator exhibiting a linear luminescent emission response to stimulating electromagnetic radiation. The nano-scintillator can include at least one nanocrystal comprising a rare earth element, a lanthanide dopant, and a spectator dopant, wherein the nanocrystal exhibits a linear luminescent emission response to stimulating electromagnetic radiation of wavelengths less than 100 nm. As one example, the nanocrystal is [Y | 03-26-2015 |
20150080306 | THERAPEUTIC AGENTS COMPRISING ELASTIC PEPTIDES - The present invention provides therapeutic agents and compositions comprising elastic peptides and therapeutic proteins. Such peptides exhibit a flexible, extended conformation. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist (e.g., GLP-1, exendin), insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability. | 03-19-2015 |
20150079064 | GENETIC CORRECTION OF MUTATED GENES - Disclosed herein are transcription activator-like effector nuclease (TALEN)-related compositions and methods of using said TALENs for correcting mutant genes. | 03-19-2015 |
20150077855 | FINITE-EMBEDDED COORDINATE DESIGNED TRANSFORMATION-OPTICAL DEVICES - The design method for complex electromagnetic materials is expanded from form-invariant coordinate transformations of Maxwell's equations to finite embedded coordinate transformations. Embedded transformations allow the transfer of electromagnetic field manipulations from the transformation-optical medium to another medium, thereby allowing the design of structures that are not exclusively invisible. A topological criterion for the reflectionless design of complex media is also disclosed and is illustrated in conjunction with the topological criterion to design a parallel beam shifter and a beam splitter with unconventional electromagnetic behavior. | 03-19-2015 |
20150077535 | SYSTEMS AND METHODS FOR STRUCTURED ILLUMINATION SUPER-RESOLUTION PHASE MICROSCOPY - Systems and methods for structured illumination super-resolution phase microscopy are disclosed. According to an aspect, an imaging system includes a light source configured to generate light. The system also includes a diffraction grating positioned to receive and diffract the output light. The system also includes a sample holder positioned to receive the diffracted light for transmission through a sample. Further, the system includes an image detector positioned to receive the light transmitted through the sample and configured to generate image data based on the received light. The system also includes a computing device configured to apply subdiffraction resolution reconstruction to the image data for generating an image of the sample. | 03-19-2015 |
20150072900 | SAMPLE PROCESSING DROPLET ACTUATOR, SYSTEM AND METHOD - Sample processing droplet actuators, systems and methods are provided. According to one embodiment, a stamping device including a droplet microactuator is provided and includes: (a) a first plate including a path or network of control electrodes for transporting droplets on a surface thereof; (b) a second plate mounted in a substantially parallel orientation with respect to the first plate providing an interior volume between the plates, the second plate including one or more stamping ports for transporting some portion or all of a droplet from the interior volume to an exterior location; (c) a port for introducing fluid into the interior volume between the plates; and (d) a path or network of reference electrodes corresponding to the path or network of control electrodes. Associated systems and methods including the stamping device are also provided. | 03-12-2015 |
20150062686 | APPARATUS AND METHOD FOR PROVIDING A SELECTIVELY ABSORBING STRUCTURE - An apparatus is described that selectively absorbs electromagnetic radiation. The apparatus includes a conducting surface, a dielectric layer formed on the conducting surface, and a plurality of conducting particles distributed on the dielectric layer. The dielectric layer can be formed from a material and a thickness selected to yield a specific absorption spectrum. Alternatively, the thickness or dielectric value of the material can change in response to an external stimulus, thereby changing the absorption spectrum. | 03-05-2015 |
20150060284 | Apparatuses and Methods for Manipulating Droplets - Apparatuses and methods for manipulating droplets are disclosed. In one embodiment, an apparatus for manipulating droplets is provided, the apparatus including a substrate, multiple arrays of electrodes disposed on the substrate, wherein corresponding electrodes in each array are connected to a common electrical signal, and a dielectric layer disposed on the substrate first side surface and patterned to cover the electrodes. | 03-05-2015 |
20150057689 | OPHTHALMIC DRUG DELIVERY DEVICE AND METHODS OF USE - The present disclosure provides an elastomeric material for the delivery of an ophthalmic agent to the eye of a subject and methods of using such material. | 02-26-2015 |
20150050734 | Carbon Nanotubes And Methods Of Use - The present disclosure provides carbon nanotube substrates, and methods of using those substrates, for the treatment and/or amelioration of neurological conditions associated with elevated levels of neural chloride. One aspect of the present disclosure provides a substrate comprising, consisting of or consisting essentially of high-conductivity few-walled CNTs dispersed thereon, wherein the CNTs comprise an intrinsic electrical conductivity of at least 2,500 S/cm. In certain embodiments, the CNTs comprise an intrinsic electrical conductivity in a range of about 1,000 S/cm to about 3,000 S/cm. In an alternative embodiment, the CNTs compromise an intrinsic electrical conductivity in a range of about 1,500 S/cm to about 2,500 S/cm. | 02-19-2015 |
20150050309 | VACCINE - The present invention relates, in-general, to Human immunodeficiency virus (HIV), and in particular to a carbohydrate-based vaccine for HIV and to methods of making and using same. | 02-19-2015 |
20150037329 | METHOD OF REDUCING TITERS OF ANTIBODIES SPECIFIC FOR A THERAPEUTIC AGENT - The present invention relates, in general, to a method of treating patients undergoing enzyme replacement therapy (ERT) or other therapy involving the administration of a proteinaceous therapeutic agent as well gene replacement therapy with non-viral or viral vectors, or other therapeutic modality or modalities, used alone or in combination, which involve the administration of exogenous substances for potential therapeutic benefit, including, but not limited to DNA vaccines, siRNA, splice-site switching oligomers (SSOs) as well as RNA-based nanoparticles (RNPs) and nanovaccines. The invention further relates to compounds and compositions suitable for use in such methods. | 02-05-2015 |
20150018281 | Compositions and Methods for Uncoupling TrkB Receptor from PLC gamma 1 for the Treatment of Epilepsy and Anxiety-Like Disorder - The invention provides pharmaceutical compositions and methods of use thereof for preventing or ameliorating disorders of the nervous system. More specifically, the invention provides pharmaceutical compositions, including phosphopeptides that when administered disrupt the physical interaction of TrkB with its signaling effector, phospholipase Cγ1 (PLCγ1). The invention further provides method of treatment comprising administering phosphopeptides that uncouple TrkB from PLCγ1 in order to prevent and/or ameliorate nervous system disorders such as epilepsy, anxiety, and seizures. | 01-15-2015 |
20140378428 | 2,5-Disubstituted-Pyridyl Nicotinic Ligands, and Methods of Use Thereof - Disclosed are heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. The compounds are useful for treating a mammal suffering from any one of a range of therapeutic indications, including Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism, trichotillomania, and hypothermia. | 12-25-2014 |
20140377261 | VACCINES AGAINST ANTIGENS INVOLVED IN THERAPY RESISTANCE AND METHODS OF USING SAME - Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER3 polypeptide. Methods of using the vaccine including the polynucleotide encoding the HER3 polypeptide to treat a cancer or precancer are also provided. | 12-25-2014 |
20140370593 | FLOW CHAMBER ASSEMBLY AND METHODS OF USING THE SAME - A flow chamber assembly for subjecting cells or other biological reagents to laminar flow conditions and methods of using the flow chamber assembly are provided herein. The flow chamber assembly includes a bottom plate having at least one well with a bottom surface adapted to receive the cells or biological reagents, a top plate having at least one flow protrusion positioned and shaped to fit into the well of the bottom plate and a sealing element positioned between the top plate and the bottom plate when the top plate and the bottom plate are attached. The flow chamber assembly is configured to allow for laminar flow of a perfusate across the cells or biological reagents along the bottom surface of the well of the bottom plate. The cells or biological reagents can be exposed to a predetermined level of shear stress. | 12-18-2014 |
20140363414 | Aggregate-Free Urate Oxidase For Preparation of Non-Immunogenic Polymer Conjugates - A naturally occurring or recombinant protein, especially a mutein of porcine urate oxidase (uricase), that is essentially free of large aggregates can be rendered substantially non-immunogenic by conjugation with a sufficiently small number of strands of polymer such that the bioactivity of the protein is essentially retained in the conjugate. Such conjugates are unusually well suited for treatment of chronic conditions because they are less likely to induce the formation of antibodies and/or accelerated clearance than are similar conjugates prepared from protein preparations containing traces of large aggregates. | 12-11-2014 |
20140358917 | SYSTEM AND METHOD FOR REMOTE IMAGE ORGANIZATION AND ANALYSIS - A system for remote image organization and analysis. The system includes at least one remotely-accessible computer including a processor, and a software program stored on a non-transitory computer readable medium accessible by the processor. The software program is operable to access at least one multi-dimensional library of image data stored on a storage medium, supplement the library by adding at least one new image to the library, share at least one image in the library between a plurality of users, wherein at least one user remotely accesses the computer, and perform at least one computational or analytical function related to an image in the library. | 12-04-2014 |
20140356291 | IDH1-Mutated Human Glioblastoma Cell Lines and Xenografts - IDH1-mutant cell lines and xenografts (e.g., IDH1R132H heterozygous and IDH1R132H homozygous) are derived from human glioblastoma multiforme (GBM) samples. Methods use said cells and xenografts as tools for determining the impact of IDH1R132H on cancer properties including cellular morphology, tumorigenesis, DNA, apoptosis, and metabolic profiles. Methods also use these cell lines for the screening and identification of candidate therapeutic targets. | 12-04-2014 |
20140350634 | DEVICES, SYSTEMS AND METHODS FOR DEEP BRAIN STIMULATION PARAMETERS - Devices, systems and methods for increasing the efficacy and/or efficiency of deep brain stimulation (DBS) using parameters of stimulation that are custom tailored to a unique set of one or more symptoms and/or to a specific patient is shown and described herein. Also disclosed are devices, systems and methods for recording pertinent neural activity during non-regular patterns of stimulation and processing techniques for these recorded signals and stimulation parameter optimization based on these neural recordings may be used to tune computational models of the stimulation patterns to reproduce the observed neural activity. | 11-27-2014 |
20140343479 | ADVANCED METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS - The present invention relates to methods for treating cell proliferation disorders comprising (1) administering to the subject at least one activatable pharmaceutical agent that is capable of activation by a simultaneous two photon absorption event and of effecting a predetermined cellular change when activated, (2) administering at least one plasmonics-active agent to the subject, and (3) applying an initiation energy from an initiation energy source to the subject, wherein the plasmonics-active agent enhances or modifies the applied initiation energy, such that the enhanced or modified initiation energy activates the activatable pharmaceutical agent by the simultaneous two photon absorption event in situ, thus causing the predetermined cellular change to occur, wherein said predetermined cellular change treats the cell proliferation related disorder, and the use of plasmonics enhanced photospectral therapy (PEPST) and exiton-plasmon enhanced phototherapy (EPEP) in the treatment of various cell proliferation disorders, and the PEPST and EPEP agents and probes | 11-20-2014 |
20140342929 | BIOMARKERS OF HIGH-GRADE SERIOUS OVARIAN CARCINOMAS - The present disclosure provides biomarkers useful for determining the prognosis of conditions such as ovarian cancer. The presently disclosed subject matter provides angiogenic biomarkers and methods and compositions for predicting overall survival (OS) in women with high-grade serious carcinomas (HGSCs). The presently disclosed subject matter provides compositions and methods that enable rationally directed therapies to improve outcome in women with HGSC. | 11-20-2014 |
20140342177 | SYNTHESIS OF CUPRONICKEL NANOWIRES AND THEIR APPLICATION IN TRANSPARENT CONDUCTING FILMS - A method of synthesis to produce a conductive film including cupronickel nanowires. Cupronickel nanowires can be synthesized from solution, homogeneously dispersed and printed to make conductive films (preferably < | 11-20-2014 |
20140341949 | VACCINE - The present invention relates, in general, to an HIV-1 vaccine and, in particular, to a B cell lineage-based vaccination protocol. | 11-20-2014 |
20140339082 | Droplet Manipulation System and Method - Methods are provided for manipulating droplets. The methods include providing the droplet on a surface comprising an array of electrodes and a substantially co-planer array of reference elements, wherein the droplet is disposed on a first one of the electrodes, and the droplet at least partially overlaps a second one of the electrodes and an intervening one of the reference elements disposed between the first and second electrodes. The methods further include activating the first and second electrodes to spread at least a portion of the droplet across the second electrode and deactivating the first electrode to move the droplet from the first electrode to the second electrode. | 11-20-2014 |
20140336202 | METHODS OF IDENTIFYING AND USING MDM2 INHIBITORS - Methods of treating subjects with cancer and screening for MDM2 inhibitors that may be effective cancer therapeutics are provided herein. The cancers that may be treated using MDM2 inhibitors using the methods described herein include those that are or may become resistant to treatment with tyrosine kinase inhibitors. Methods of treating subjects with cancers that have, or develop in response to treatment with tyrosine kinase inhibitors, elevated levels of MDM2, Mcl-1 or PP5 or decreased levels of Huwe1 or CAS using MDM2 inhibitors are provided herein. The MDM2 inhibitors may be effective at treating these cancers alone or in combination with a tyrosine kinase inhibitor regardless of p53 status (mutant or wild-type) of the cancer. | 11-13-2014 |
20140332416 | METHOD FOR LIBERATING AND DETECTING NITRIC OXIDE FROM NITROSOTHIOLS AND IRON NITROSYLS IN BLOOD - Amount of combined nitric oxide or nitric oxide presented as iron nitrosyls in a blood sample is determined by directing a low power electromagnetic radiation beam at a blood sample to liberate nitric oxide gas, dissolving the liberated nitric oxide gas and electrochemically detecting amount of dissolved nitric oxide gas. | 11-13-2014 |
20140329307 | Method and Device for Conducting Biochemical or Chemical Reactions at Multiple Temperatures - Methods and devices for conducting chemical or biochemical reactions that require multiple reaction temperatures are described. The methods involve moving one or more reaction droplets or reaction volumes through various reaction zones having different temperatures on a microfluidics apparatus. The devices comprise a microfluidics apparatus comprising appropriate actuators capable of moving reaction droplets or reaction volumes through the various reaction zones. | 11-06-2014 |
20140323946 | PHOSPHORS AND SCINTILLATORS FOR LIGHT STIMULATION WITHIN A MEDIUM - A system and method for light stimulation within a medium. The system has a reduced-voltage x-ray source configured to generate x-rays from a peak applied cathode voltage at or below 105 kVp, and a plurality of energy-emitting particles in the medium which, upon radiation from the x-ray source, radiate at a first lower energy than the x-ray source to interact with at least one photoactivatable agent in the medium. The method introduces the plurality of energy-emitting particles into the medium, radiates the energy-emitting particles in the medium with x-rays generated from a peak applied cathode voltage at or below 105 kVp; and emits a lower energy than the x-ray source to interact with the medium or with at least one photoactivatable agent in the medium. | 10-30-2014 |
20140323391 | BIOMARKERS FOR THE MOLECULAR CLASSIFICATION OF BACTERIAL INFECTION - Disclosed herein are biomarkers useful for identifying and/or classifying bacterial infections in a subject. | 10-30-2014 |
20140315984 | Methods and Compositions for Treatment of Diabetes and Related Disorders - The present invention provides a method of stimulating growth of a pancreatic islet beta cell and/or enhancing glucose stimulated insulin secretion of a pancreatic islet beta cell, comprising delivering to the cell an exogenous nucleotide sequence encoding Nkx6.1 transcription factor. | 10-23-2014 |
20140315823 | PEPTIDE COMPOUNDS FOR SUPPRESSING INFLAMMATION - Provided herein are peptides that exhibit ApoE biological activity, as well as compositions and pharmaceutical formulations that include the peptides. The peptides, compositions, and methods disclosed herein have broad applications as they can be used to treat a broad spectrum of injury, diseases, disorders, and clinical indications. | 10-23-2014 |
20140314881 | NOVEL MEDICAL USES FOR NO AND NO DONOR COMPOUNDS - A body part is preserved using nitric oxide and/or a nitric oxide donor that does not directly release nitric oxide or a red blood cell nitrosylating agent, preferably ethyl nitrite to facilitate oxygen supply. A subject at risk for developing high altitude illness is administered a red blood nitrosylating agent in gaseous form that does not directly release nitric oxide, preferably ethyl nitrite. | 10-23-2014 |
20140314371 | POLYMER OPTICAL ISOLATOR - Various optical isolators are disclosed. One embodiment provides an optical isolator comprising a waveguide that includes polymer magneto-optical media. In a particular embodiment, the waveguide is dimensioned for single mode operation in the selected isolation range. A cross-section of the waveguide is inhomogeneous in terms of magneto-optical materials. Polymer magneto-optical material is a part of the optical waveguide structure. The inhomogeneity induces the propagation constant shift, which is propagation-direction-dependent. An embodiment is characterized by a cutoff frequency for forward propagating waves that is different than the cutoff frequency for reverse waves; the dimensions and direction of magnetization of the waveguide can be tailored so that, in a particular embodiment, the cutoff frequency for forward propagating waves is lower than the cutoff frequency for reverse waves. | 10-23-2014 |
20140309177 | COMPOSITIONS AND METHODS FOR THE INDUCTION AND TUNING OF GENE EXPRESSION - Disclosed herein are compositions of transcription activator-like effectors transcription factors and methods of using said compositions for inducing gene expression of mammalian genes. | 10-16-2014 |
20140302062 | HERPES SIMPLEX VIRUS - The present invention relates, in general to herpes simplex virus (HSV) and, particular, to antibodies that are specific for glycoprotein D (gD) of HSV. The invention also relates to prophylactic and therapeutic uses of such antibodies. | 10-09-2014 |
20140302043 | BROADLY NEUTRALIZING HUMAN ANTIBODY THAT RECOGNIZES THE RECEPTOR-BINDING POCKET OF INFLUENZA HEMAGGLUTININ - The invention features a novel influenza antibody that specifically binds to influenza hemagglutinin and reduces or inhibits hemagglutinin binding to sialic acid. The invention also provides methods, compositions, and kits featuring the novel antibody and its use in preventing or treating influenza infection. | 10-09-2014 |
20140296152 | Stem Cell Derived Factors for Treating Pathologic Conditions - A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death an/or tissue injury associated with ischemic conditions. | 10-02-2014 |
20140287032 | Treatment Method and Product for Uterine Fibroids using Purified Collagenase - The invention relates to compositions and methods for treating uterine fibroids, wherein a uterine fibroid treatment agent comprising collagenase in an amount effective to cause shrinkage of uterine fibroids is injected or inserted into the uterine fibroid. | 09-25-2014 |
20140276049 | ULTRASOUND SYSTEMS, METHODS AND COMPUTER PROGRAM PRODUCTS FOR ESTIMATING TISSUE DEFORMATION WITH HARMONIC SIGNALS - An ultrasound system for estimating tissue deformation in ultrasound elasticity imaging includes a controller configured to deliver a plurality of tracking pulses and to obtain a plurality of data sets for a region of interest from an ultrasound transducer array; a harmonic data analyzing circuit configured to receive the plurality of data sets and to extract one or more harmonic data sets including harmonic signals from the plurality of image data sets; and a displacement estimator circuit configured to estimate tissue deformation in the region of interest responsive to the one or more harmonic data sets. | 09-18-2014 |
20140275226 | METHOD OF CONTROLLING COAGULATION - The present invention relates, in general, to methods of controlling coagulation, and in particular, to methods of effecting neutralizable rapid onset anticoagulation, and to compounds and compositions suitable for use in such methods. | 09-18-2014 |
20140275225 | MODULATORS OF PHARMACOLOGICAL AGENTS - The biological activity of nucleic acid ligand is regulated (i.e. enhanced or inhibited) in vivo to produce a desired biological effect. This is accomplished through the administration of a modulator, or regulator, that changes the binding of the nucleic acid ligand for its target or that degrades or otherwise cleaves, metabolizes or breaks down the nucleic acid ligand while the ligand is still exerting its effect. Modulators of the present invention can be administered in real time as needed based on various factors, including the progress of the patient, as well as the physician's discretion in how to achieve optimal therapy. Thus, this invention provides for the first time a regulatable therapeutic regime in the course of nucleic acid ligand therapy. | 09-18-2014 |
20140274955 | PROCHELATORS AS BROAD-SPECTRUM ANTIMICROBIAL AGENTS AND METHODS OF USE - The present disclosure provides methods of treating (including ameliorating and/or preventing) pathogenic infections by administering a therapeutically effective amount of a prochelator. The present disclosure further provides pharmaceutical compositions and a kit comprising the prochelator therein. | 09-18-2014 |
20140274905 | METHODS AND COMPOUNDS FOR CALCIUM ION CHANNEL REGULATION - The present invention generally relates to methods of modulating Ca | 09-18-2014 |
20140271612 | Treatment Method and Product for Uterine Fibroids using Purified Collagenase - The invention relates to compositions and methods for treating uterine fibroids, wherein a uterine fibroid treatment agent comprising collagenase in an amount effective to cause shrinkage of uterine fibroids is injected or inserted into the uterine fibroid. | 09-18-2014 |
20140261646 | ADVANCED SEMICONDUCTOR-CONDUCTOR COMPOSITE PARTICLE STRUCTURES FOR SOLAR ENERGY CONVERSION - An electrode for solar conversion including a porous structure configured to contain therein at least one of a catalyst, a chromophore, and a redox couple. The porous structure has a set of electrically conductive nanoparticles adjoining each other. The set of electrically conductive nanoparticles forms a meandering electrical path connecting the nanoparticles together. The porous structure has an atomic layer by layer deposited semiconductive coating disposed conformally on the electrically conductive nanoparticles to form an exterior surface for reception of charge carriers. | 09-18-2014 |
20140248311 | N-TERMINAL DELETED GP120 IMMUNOGENS - The present invention relates, in general, to human immunodeficiency virus (HIV), and in particular to a vaccine for HIV-1 and to methods of making and using same. | 09-04-2014 |
20140247920 | APPARATUS FOR CODED APERTURE X-RAY SCATTER IMAGING AND METHOD THEREFOR - A system and method for producing images of the structure and composition of an object based on measurements of the low-angle x-ray diffraction properties of the object. The imaging system includes a coded aperture that encodes spatial and spectral features onto radiation scattered from image points within the object. The radiation is detected at a two-dimensional array of detectors, whose output is deconvolved and processed to estimate a three-dimensional image having molecular specificity. | 09-04-2014 |
20140243934 | NON-INVASIVE ENERGY UPCONVERSION METHODS AND SYSTEMS - Products, compositions, systems, and methods for modifying a target structure. The methods may be performed in a non-invasive manner by placing a nanoparticle having a metallic shell on at least a fraction of a surface in a vicinity of a target structure in a subject and applying an initiation energy thus producing an effect on or change to the target structure directly or via a modulation agent. The nanoparticle is configured, upon exposure to a first wavelength λ | 08-28-2014 |
20140243695 | METHOD AND SYSTEM FOR EVALUATING STABILITY OF CARDIAC PROPAGATION RESERVE - A method of determining the susceptibility to ventricular arrhythmias in a subject, comprises the steps of: (a) collecting (e.g., by surface EKG or intracardiac EKG) at least one QT and DI interval data set from the subject during a stage of gradually increasing heart rate or a stage of gradually decreasing heart rate; (b) determining (e.g., by applying low- and high pass filtering) low-frequency QT-DI interval trends and high-frequency QT-DI fluctuation signals in said at least one QT and DI interval data set; (c) finding a plurality of correlated and anti-correlated portions between said high-frequency QT-DI fluctuation signals; (d) determining corresponding regression lines for said correlated and anti-correlated portions; (e) finding a plurality of (or in some embodiments all) steady state QT-DI points designated by intersections between said low frequency QT-DI trends and said corresponding regression lines; (f) fitting action potential durations computed from a rate dependent reaction-diffusion model to corresponding ones of said steady state QT-DI points to give (i) a model excitation threshold and (ii) a minimal level of refractoriness at a plurality of (or in some embodiments all of) said steady state QT-DI points; (g) at the steady state QT-DI point corresponding to the highest heart rate in said QT and DI interval data set, determining the difference between said minimal level of refractoriness and a model critical excitation threshold for a stable solitary pulse corresponding to the rate dependent reaction diffusion model of step (f) to give a reserve of refractoriness (RoR); (h) fitting action potential durations computed from a rate dependent reaction-diffusion model to said correlated and anti-correlated portions to give a rate of adaptation of each model excitation threshold to a corresponding steady state value at a plurality of (or in some embodiments all of) said steady state QT-DI points; (i) at the steady state QT-DI point corresponding to the highest heart rate in said QT and DI interval data set, determining the inverse of said rate of adaptation to give a reserve of memory (RoM); (j) combining said reserve of refractoriness (RoR) and said reserve of memory (RoM) to produce a metric of stability-of-propagation reserve (SoPR) in said subject, a higher value of SoPR indicating lower susceptibility to ventricular arrhythmias in said subject. Systems and apparatus for carrying out the method are also described. | 08-28-2014 |
20140243294 | METHOD OF ACTIVATION OF OXAZAPHOSPHORINES - The present invention provides a method of hydroxylating or oxidizing a compound of interest in a subject (e.g., a cytotoxic oxazaphosphorine prodrug), by administering the compound of interest to the subject; and concurrently administering the subject a metalloporphyrin in an amount effective to hydroxylate or oxidize the compound of interest in the subject. | 08-28-2014 |
20140243226 | SIGNATURES OF RADIATION RESPONSE - The present invention relates, in general, to gene expression profiles, and in particular, to a peripheral blood gene expression profile of an environmental exposure, ionizing radiation. The invention further relates to methods of screening patients for radiation exposure based on gene expression profiling and to kits suitable for use in such methods. | 08-28-2014 |
20140241605 | Methods and computer program products for quantitative three-dimensional image correction and clinical parameter computation in optical coherence tomography - Methods and computer program products for quantitative three-dimensional (“3D”) image correction in optical coherence tomography. Using the methods and computer program products, index interface (refracting) surfaces from the raw optical coherence tomography (“OCT”) dataset from an OCT system can be segmented. Normal vectors or partial derivatives of the curvature at a refracting surface can be calculated to obtain a refracted image voxel. A new position of each desired refracted image voxel can be iteratively computed. New refracted corrected voxel positions to an even sampling grid can be interpolated to provide corrected image data. In some embodiments, clinical outputs from the corrected image data can be computed. | 08-28-2014 |
20140235528 | INHIBITING GS-FDH TO MODULATE NO BIOACTIVITY - Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase. | 08-21-2014 |
20140222117 | PLASMONIC ASSISTED SYSTEMS AND METHODS FOR INTERIOR ENERGY-ACTIVATION FROM AN EXTERIOR SOURCE - A method and a system for producing a change in a medium disposed in an artificial container. The method places in a vicinity of the medium at least one of a plasmonics agent and an energy modulation agent. The method applies an initiation energy through the artificial container to the medium. The initiation energy interacts with the plasmonics agent or the energy modulation agent to directly or indirectly produce the change in the medium. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the plasmonics agent or the energy modulation agent. | 08-07-2014 |
20140221219 | OLIGODENDROGLIOMA DRIVE GENES - Oligodendrogliomas are the second most common malignant brain tumor in adults. These tumors often contain a chromosomal abnormality involving a pericentromeric fusion of chromosomes 1 and 19, resulting in losses of the entire short arm of the former and the long arm of the latter. To identify the molecular genetic basis for this alteration, we performed exomic sequencing of seven anaplastic oligodendrogliomas with chromosome 1p and 19q losses. Among other changes, we found that that CIC (homolog of the | 08-07-2014 |
20140218748 | SYSTEMS AND METHODS OF ANGLE-RESOLVED LOW COHERENCE INTERFEROMETRY BASED OPTICAL CORRELATION - Systems and methods of angle-resolved low coherence interferometry based optical correlation are disclosed. According to an aspect, a method includes directing a sample beam towards a sample for producing a scattered sample beam from the sample. The method also includes receiving the scattered sample beam at a multitude of scattering angles in at least two directions. Further, the method includes cross-correlating the scattered sample beam with a reference beam to produce a two-dimensional angle and depth resolved profile of the sample scattered beam. The method also includes processing the two-dimensional angle and depth scattered profile to obtain correlated information about scattering structures in the sample. | 08-07-2014 |
20140213638 | Compositions and Biomarkers for Heart Disease, Injury and Failure and Methods of Use - The present disclosure provides biomarkers useful for determining the risk of, prognosis of, and/or diagnosis of conditions such as ischemic and/or non-ischemic heart failure in a subject. | 07-31-2014 |
20140213516 | THERAPEUTIC AGENTS COMPRISING ELASTIC PEPTIDES - The present invention provides therapeutic agents and compositions comprising elastic peptides and therapeutic proteins. Such peptides exhibit a flexible, extended conformation. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist (e.g., GLP-1, exendin), insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability. | 07-31-2014 |
20140205607 | FOCUSED EVOLUTION OF HIV-1 NEUTRALIZING ANTIBODIES REVEALED BY CRYSTAL STRUCTURES AND DEEP SEQUENCING - Antibody VRC01 represents a human immunoglobulin that neutralizes—˜90% of diverse HIV-1 isolates. To understand how such broadly neutralizing HIV-1 antibodies develop and recognize the viral envelope, we used X-ray crystallography and 454 pyrosequencing to characterize additional antibodies from HIV-1-infected individuals. Crystal structures revealed a convergent mode of binding of different antibodies to the same CD4-binding-site epitope. Antibody recognition was achieved through the evolution of complementary contact domains that were generated in diverse ways. Phylogenetic analysis of expressed heavy and light chains determined by deep sequencing revealed a common pathway of antibody heavy chain maturation confined to IGHV1-2*02 lineage that could pair with different light chains. The maturation pathway inferred by antibodyomics reveals that diverse antibodies evolve to a highly affinity-matured state to recognize an invariant viral structure, providing insight into the development and evolution of broadly neutralizing HIV-1 immunity. | 07-24-2014 |
20140192254 | QUASI-MONOCENTRIC-LENS-BASED MULTI-SCALE OPTICAL SYSTEM - Optical systems based on an objective lens comprising one or more plastic lens elements are disclosed. The inclusion of plastic lens element reduces one or more of system cost, size, weight, and/or complexity. The chromatic performance of some imaging systems in accordance with the present invention is improved by incorporation of a diffractive surface into the entry surface of the objective lens. | 07-10-2014 |
20140187764 | GENETIC ALTERATIONS IN ISOCITRATE DEHYDROGENASE AND OTHER GENES IN MALIGNANT GLIOMA - We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas. | 07-03-2014 |
20140176710 | MULTISCALE TELESCOPIC IMAGING SYSTEM - A multiscale telescopic imaging system is disclosed. The system includes an objective lens, having a wide field of view, which forms an intermediate image of a scene at a substantially spherical image surface. A plurality of microcameras in a microcamera array relay image portions of the intermediate image onto their respective focal-plane arrays, while simultaneously correcting at least one localized aberration in their respective image portions. The microcameras in the microcamera array are arranged such that the fields of view of adjacent microcameras overlap enabling field points of the intermediate image to be relayed by multiple microcameras. The microcamera array and objective lens are arranged such that light from the scene can reach the objective lens while mitigating deleterious effects such as obscuration and vignetting. | 06-26-2014 |
20140163303 | PLASMONIC ASSISTED SYSTEMS AND METHODS FOR INTERIOR ENERGY-ACTIVATION FROM AN EXTERIOR SOURCE - A method and a system for producing a change in a medium disposed in an artificial container. The method places in a vicinity of the medium at least one of a plasmonics agent and an energy modulation agent. The method applies an initiation energy through the artificial container to the medium. The initiation energy interacts with the plasmonics agent or the energy modulation agent to directly or indirectly produce the change in the medium. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the plasmonics agent or the energy modulation agent. | 06-12-2014 |
20140148414 | PROCHELATORS USEFUL FOR INHIBITING METAL-ASSOCIATED TOXICITY - Prochelator compounds of Formula I or Formula II: | 05-29-2014 |
20140141429 | METHODS OF IDENTIFYING INDIVIDUALS AT RISK OF PERIOPERATIVE BLEEDING, RENAL DYSFUNCTION OR STROKE - The present invention relates, in general, to perioperative bleeding and, in particular, to methods of identifying individuals at risk of perioperative bleeding. | 05-22-2014 |
20140139623 | PANORAMIC MULTI-SCALE IMAGER AND METHOD THEREFOR - A panoramic imager comprising a mirror and a multi-scale imaging system is presented. The multi-scale imaging system comprises an objective lens and a plurality of cameras that is arranged in a non-planar arrangement at the image field of the objective lens. The objective lens reduces a first aberration introduced by the mirror, and each camera further reduces any residual first aberration. As a result, panoramic imagers of the present invention can provide improved image quality and higher resolution than panoramic imagers of the prior art. | 05-22-2014 |
20140127193 | METHODS OF DEVELOPING A PROGNOSIS FOR PANCREATIC CANCER AND PREDICTING RESPONSIVENESS TO CANCER THERAPEUTICS - Methods of predicting responsiveness of a cancer in a subject to a cancer therapy including a VEGF targeting agent are provided herein. The methods include detecting the expression level of at least one biomarker selected from ANG-2, SDF-1 and VEGF-D in a sample from the subject and using the expression levels to determine whether the VEGF targeting agent will be effective to treat the cancer in the subject. The predictions may be used to develop treatment plans for the subjects. Methods of developing a prognosis for a subject with pancreatic cancer are also provided. These methods include determining the expression level of IGFBP-1, PDGF-AA and at least one of IL-6 or CRP in a sample from a subject with pancreatic cancer. | 05-08-2014 |
20140122951 | SCAN TEST OF DIE LOGIC IN 3D ICs USING TSV PROBING - A test architecture for 3D ICs is provided in which Through-Silicon-Vias and die logic can be tested pre-bonding dies in the stack for the 3D ICs. Post-bond scan test architecture is reconfigured to be accessed during pre-bond testing through using stratigically placed MUXs and TSVs. By connecting post-bond architecture including scan flops and boundary registers to gated scan flops used in TSV testing, an internal chain of scan flops such as typically used in post-bond testing can be selectively connected to gated scan flops connected to one end of each TSV for pre-bond testing of the internal logic through the TSVs. | 05-01-2014 |
20140099268 | COSMETIC AND PHARMACEUTICAL COMPOSITIONS AND METHODS USING 2-DECARBOXY-2-PHOSPHINICO DERIVATIVES - A method for treating hair loss in mammals uses compositions containing 2-decarboxy-2-phosphinico prostaglandin derivatives. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth. Compositions containing 2-decarboxy-2-phosphinico prostaglandin derivatives can also be used to lower intraocular pressure and treat bone disorders. | 04-10-2014 |
20140080797 | SUBSTITUTED PORPHYRINS - Substituted metalloporphyrin compounds are described, along with pharmaceutical compositions containing the same, and methods of use thereof in protecting cells from oxidant-induced toxicity and pathological conditions such as inflammatory lung disease, neurodegenerative conditions, radiation injury, cancer, diabetes, cardiac conditions and sickle cell disease. Mn(III) porphyrins bearing oxygen atoms within side chains are particularly described. | 03-20-2014 |
20140056896 | ANTI-CD19 ANTIBODIES AND USES IN B CELL DISORDERS - The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies and autoimmune diseases and disorders, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies. | 02-27-2014 |
20140050740 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TISSUE FIBROSIS - Provided are methods of treating tissue fibrosis comprising administering to a subject in need of treatment an effective amount of an agent that inhibits a hyaluron synthase (HAS) or CD44. Further provided are methods of inhibiting myofibroblast invasion, or of reducing matrix deposition in the lung, the methods comprising administering to a subject in need of treatment an effective amount of an agent that inhibits a HAS or CD44. Further provided are methods of determining the progression of pulmonary fibrosis, the methods comprising determining the level of matrix metalloproteinase expression in a cell, and comparing the level of expression to that of a control cell, wherein an increased level of expression relative to the control cell indicates progression of the disease. | 02-20-2014 |
20140039280 | Non-Invasive Diagnostic Device for Early Detection of Infection and Inflammation and Methods of Use - The present disclosure provides, in part, a self-contained, point-of-care device for the early detection of infection, or other pathologic conditions that can lead to system inflammation, by the detection of the endogenous gaseous mediator nitric oxide (NO.) and methods of use. | 02-06-2014 |
20140038898 | PEPTIDES FOR SUPPRESSING INFLAMMATION - Provided herein are peptides that exhibit ApoE biological activity, as well as compositions and pharmaceutical formulations that include the peptides. The peptides, compositions, and methods disclosed herein have broad applications as they can be used to treat a broad spectrum of injury, diseases, disorders, and clinical indications. | 02-06-2014 |
20140032244 | SYSTEMS AND METHODS FOR TELEHEALTH DELIVERY AND ANALYSIS - Systems and methods for telehealth delivery and analysis are disclosed. According to an aspect, a method includes receiving medical data associated with a patient. Further, the method includes determining consultation communication data associated with one or more communications between a healthcare professional and the patient. The method also includes generating statistical analysis data based on the medical data and the consultation communication data. | 01-30-2014 |
20140024600 | METHODS AND COMPOSITIONS FOR MODULATING DRUG-POLYMER ARCHITECTURE, PHARMACOKINETICS AND BIODISTRIBUTION - Drug-polymer chemotherapeutics are provided having improved therapeutic efficacy and reduced dose-limiting toxicity. Methods are also provided for modulating the architecture, pharmacokinetics and biodistribution of drug-polymers and for reducing the dependence of transition temperature on concentration for drug-polymers. | 01-23-2014 |
20140024587 | COMPOSITIONS AND METHODS FOR TREATING HAIR LOSS USING NON-NATURALLY OCCURRING PROSTAGLANDINS - A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth. | 01-23-2014 |
20140023683 | IDENTIFICATION OF TRANSMITTED HEPATITIS C VIRUS (HCV) GENOMES BY SINGLE GENOME AMPLIFICATION - This invention provides methods for identifying HCV genomes and more specifically, methods for identifying nucleotide sequence of viral structural proteins at the time of HCV viral transmission. The method of the invention utilizes single genome amplification and sequencing of circulating virus as well as phylogenetic analysis of the resulting nucleotide sequence for identifying transmitted HCV genomes. Also provided are HCV genomes and corresponding nucleotide sequence for transmitted and circulating HCV virus. The invention further provides methods of administering a vaccine comprising one or more identified transmitted HCV sequences. | 01-23-2014 |
20140018721 | Arteriovenous Graft for Hemodialysis with Puncture-Resistant Posterior and Side Walls - An arteriovenous dialysis access graft configured to be implanted in a subject includes: at least one flexible conduit having first and second end portions, wherein the first end portion is configured to connect to an artery of the subject and the second end portion is configured to connect to a vein of the subject such that blood flows through the at least one conduit; and at least one cannulation chamber positioned between the first end portion and the second end portion of the at least one conduit. The chamber includes: an elongated housing having an inlet and an outlet, a posterior wall, a pair of sidewalls, and an open anterior portion defining a cannulation port; and a self-sealing material extending across the cannulation port. The posterior wall and the sidewalls of the housing are formed of a substantially rigid material. | 01-16-2014 |
20140017266 | ANTI-PODOPLANIN ANTIBODIES AND METHODS OF USE - Recombinant scFv-immunotoxins target tumor cells expressing human podoplanin but not podoplanin-negative or normal cells. The immunotoxins can be used for treatment of malignant glioma patients or any malignant tumor expressing podoplanin. One such immunotoxin comprises a modified | 01-16-2014 |
20140011281 | Direct Reprogramming of Cells to Cardiac Myocyte Fate - A method for promoting conversion of cells into cardiomyocytic tissue is carried out by contacting fibrotic tissue (e.g., scar tissue) with a microRNA oligonucleotide or combination of microRNA oligonucleotides. The methods lead to direct reprogramming of fibroblasts to cardiomyocytes or cardiomyoblasts. | 01-09-2014 |
20140010797 | Fusion Molecules of Rationally-Designed DNA-Binding Proteins and Effector Domains - Targeted transcriptional effectors (transcription activators and transcription repressors) derived from meganucleases are described. Also described are nucleic acids encoding same, and methods of using same to regulate gene expression. The targeted transcriptional effectors can comprise (i) a meganuclease DNA-binding domain lacking endonuclease cleavage activity that binds to a target recognition site; and (ii) a transcription effector domain. | 01-09-2014 |
20130344497 | USE OF NOVEL CYTOKINE RECEPTORS AS BIOMARKERS AND THERAPEUTIC TARGETS IN HUMAN CANCER - Nucleic acids encoding erythropoietin isoforms are described herein, as well as the encoded isoforms, methods of detecting the same, and methods of screening for and treating cancer. | 12-26-2013 |
20130339433 | METHOD AND APPARATUS FOR CONTENT RATING USING REACTION SENSING - A system that incorporates teachings of the subject disclosure may include, for example, receiving segment ratings and semantic labels associated with media content from a group of first communication devices, analyzing the segment ratings and the semantic labels to identify universal segments among the plurality of segments that satisfy a threshold based on common segment ratings and common semantic labels; and providing universal reactions and an identification of the universal segments to a second communication device for generation of a content rating for the media content based on the universal segments and reaction data collected by sensors of the second communication device, where the universal reactions are representative of the common segment ratings and the common semantic labels for the universal segments. Other embodiments are disclosed. | 12-19-2013 |
20130338192 | METHOD FOR AUGMENTING THE EFFECTS OF SEROTONIN REUPTAKE INHIBITORS - A method of treating a subject for a serotonergic neurotransmission dysregulation disorder, comprises administering the subject a serotonin enhancer (e.g., a serotonin reuptake inhibitor) in an amount effective to treat the disorder; and concurrently administering the subject 5-hydroxytryptophan in an amount effective to enhance the activity of the serotonin enhancer, (e.g., serotonin reuptake inhibitor). In preferred embodiments the disorder is depression, anxiety, or substance abuse. | 12-19-2013 |
20130335256 | METAMATERIAL DEVICES AND METHODS OF USING THE SAME - Compressive imaging captures images in compressed form, where each sensor does not directly correspond with a pixel, as opposed to standard image capture techniques. This can lead to faster image capture rates due to lower I/O bandwidth requirements, and avoids the need for image compression hardware, as the image is captured in compressed form. Measuring the transformation of an emitted multimodal signal is one method of compressive imaging. Metamaterial antennas and transceivers are well suited for both emitting and receiving multimodal signals, and are thus prime candidates for compressive imaging. | 12-19-2013 |
20130331326 | METHOD OF INDUCING HEMATOPOIETIC RECONSTRUCTION - The present invention relates, in general, to hematopoietic reconstruction and, in particular, to a method of inducing hematopoietic reconstruction using EGF. The invention also relates to compounds and compositions suitable for use in such a method. | 12-12-2013 |
20130324416 | Methods and Compositions for Correlating Genetic Markers with Cardiovascular Disease - The present invention provides methods of identifying a subject having an increased or decreased risk of developing cardiovascular disease, comprising: a) correlating the presence of one or more genetic markers in chromosome 3q13.31 with an increased or decreased risk of developing cardiovascular disease; and b) detecting the one or more genetic markers of step (a) in the subject, thereby identifying the subject as having an increased or decreased risk of developing cardiovascular disease. Also provided are methods of identifying subjects with cardiovascular disease as having a good or poor prognosis, as well as methods of identifying effective treatment regimens for cardiovascular disease, based on correlation with genetic markers in chromosome 3q13.31. | 12-05-2013 |
20130310893 | SPATIALLY SELECTIVE VAGUS NERVE STIMULATION - By targeting on selected branches or fascicles of a vagus nerve using electrode placement and/or selection, one or more target branches of the vagus nerve are substantially activated by electrical stimulation pulses delivered to a branch without substantially activating one or more non-target branches. In one embodiment, vagus nerve stimulation is delivered through an electrode placed on a thoracic vagus nerve that is separated from a recurrent laryngeal nerve, such that the vagus nerve is stimulated without causing laryngeal muscle contractions. In another embodiment, vagus nerve stimulation is delivered through a multi-contact electrode with one or more contacts selected for delivering the electrical stimulation pulses to stimulate the vagus nerve without causing laryngeal muscle contractions. | 11-21-2013 |
20130310538 | METHODS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS WITH ENHANCED PHARMACOLOGICAL PROPERTIES - Provided herein are methods of enhancing in vivo efficacy of an active agent, comprising: administering to a subject an active agent that is coupled to a bioelastic polymer or elastin-like peptide, wherein the in vivo efficacy of the active agent is enhanced as compared to the same active agent when administered to the subject not coupled to (or not associated with) a bioelastic polymer or ELP. | 11-21-2013 |
20130309244 | METHODS AND COMPOSITIONS COMBINING IMMUNOTHERAPY WITH MONOCYTE ACTIVATION - Methods of enhancing the effectiveness of an antibody-based therapeutic agent are provided herein. The methods include administering an antibody-based therapeutic and a composition capable of preferentially activating monocytes or macrophages or preferentially depleting B10 cells to a subject in need of such treatment. The subject may have cancer, an autoimmune disease, an infectious disease or an immunodeficiency. The composition capable of preferentially activating monocytes or macrophages may be a TLR3 agonist. The composition capable of preferentially depleting B10 cells may be a CD19 antibody. Pharmaceutical compositions comprising an antibody-based therapeutic agent and a composition capable of preferentially activating monocytes or macrophages or preferentially depleting B10 cells are also provided. | 11-21-2013 |
20130304161 | NON-REGULAR ELECTRICAL STIMULATION PATTERNS FOR TREATING NEUROLOGICAL DISORDERS - Systems and methods for stimulation of neurological tissue generate stimulation trains with temporal patterns of stimulation, in which the interval between electrical pulses (the inter-pulse intervals) changes or varies over time. Compared to conventional continuous, high rate pulse trains having regular (i.e., constant) inter-pulse intervals, the non-regular (i.e., not constant) pulse patterns or trains that embody features of the invention provide a lower average frequency. | 11-14-2013 |
20130281497 | MACROCYCLIC COMPOUNDS AND METHODS OF TREATMENT - The instant invention describes macrocyclic compounds having therapeutic activity, and methods of treating disorders such as methods of modulating bone processes, and methods of treating bone-related disease, disorders, and symptoms thereof. | 10-24-2013 |
20130273103 | POLYVALENT IMMUNOGEN - The present invention relates, in general, to HIV-1 and, in particular, to polyvalent immunogens suitable for use in inducing an immune response to HIV-1 in a patient, and to methods of identifying such immunogens. The invention further relates to methods of inducing an anti-HIV-1 immune response using such immunogens. | 10-17-2013 |
20130267543 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF - The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity. | 10-10-2013 |
20130265582 | SYSTEMS AND METHODS FOR ENDOSCOPIC ANGLE-RESOLVED LOW COHERENCE INTERFEROMETRY - Fourier domain a/LCI (faLCI) system and method which enables in vivo data acquisition at rapid rates using a single scan. Angle-resolved and depth resolved spectra information is obtained with one scan. The reference arm can remain fixed with respect to the sample due to only one scan required. A reference signal and a reflected sample signal are cross-correlated and dispersed at a multitude of reflected angles off of the sample, thereby representing reflections from a multitude of points on the sample at the same time in parallel. Information about all depths of the sample at each of the multitude of different points on the sample can be obtained with one scan on the order of approximately 40 milliseconds. From the spatial, cross-correlated reference signal, structural (size) information can also be obtained using techniques that allow size information of scatterers to be obtained from angle-resolved data. | 10-10-2013 |
20130254909 | SYNTHETIC REGULATION OF GENE EXPRESSION - Synthetic regulation of gene expression is provided. In some embodiments, synthetic regulatory constructs are provided. In some embodiments, a synthetic regulatory construct expresses a heterologous gene in a selected cell type. In some embodiments, methods of expressing a heterologous gene in a selected cell type are provided. | 09-26-2013 |
20130254196 | COST-BASED OPTIMIZATION OF CONFIGURATION PARAMETERS AND CLUSTER SIZING FOR HADOOP - Cost-based optimization of configuration parameters and cluster sizing for distributed data processing systems are disclosed. According to an aspect, a method includes receiving at least one job profile of a MapReduce job. The method also includes using the at least one job profile to predict execution of the MapReduce job within a plurality of different predetermined settings of a distributed data processing system. Further, the method includes determining one of the predetermined settings that optimizes performance of the MapReduce job. The method may also include automatically adjusting the distributed data processing system to the determined predetermined setting. | 09-26-2013 |
20130253035 | CAMKK-BETA AS A TARGET FOR TREATING CANCER - Provided herein are compounds, compositions, including pharmaceutical compositions, having anti-cancer activity. Also provided are methods for diagnosing, detecting, and treating cancer in a subject, as well as a method for evaluating cancer stage in a subject, wherein the methods include determining the amount of a Ca | 09-26-2013 |
20130245253 | Conjugated Neuroactive Steroid Compositions And Methods Of Use - The present disclosure provides modified neuroactive steroids. The modified neuroactive steroids may comprise, consist of, or consist essentially of a therapeutic agent and/or a modifying moiety. The modified neuroactive steroid can have modified characteristics as compared to native neuroactive steroids that do not include a modifying moiety and/or therapeutic agent. The modified neuroactive steroid may be, for example, modified pregnenolone, pregnenolone metabolites, allopregnanolone, and/or allopregnanolone metabolites. The modified neuroactive steroids can be used to treat, prevent and/or ameliorating a phenotypic state of interest in a subject. | 09-19-2013 |
20130245244 | Antibodies and Immunotoxins that Target Human Glycoprotein NMB - The invention provides high affinity antibodies suitable for forming immunotoxins that inhibit the growth of cells expressing human glycoprotein NMB, including glioblastoma multiforme cells, anaplastic astrocytoma cells, anaplastic oligodendroglioma cells, oligodendroglioma cells, and melanoma cells. The antibodies may be formed in cells transformed with an isolated nucleic acid encoding a polypeptide comprising an antibody heavy chain variable region (“VH”) and an antibody light chain variable region (“VL”). Such nucleic acids are provided. | 09-19-2013 |
20130243850 | ADJUVANT - The present invention relates, in general, to human immunodeficiency vims (HIV- | 09-19-2013 |
20130242060 | MULTISCALE OPTICAL SYSTEM HAVING DYNAMIC CAMERA SETTINGS - A multiscale imaging system including microcameras having controllable focus, dynamic range, exposure, and magnification is disclosed. The objective lens forms a three-dimensional image field of a scene. Image regions of the image field are relayed by the microcameras onto their respective focal-plane arrays, which collectively provide a plurality of digital sub-images of the scene. The digital sub-images can then be used to form a composite digital image of the scene that can have enhanced depth-of-field, enhanced dynamic range, parallax views of the scene, or three-dimensionality. | 09-19-2013 |
20130231323 | ETHYNYLBENZENE DERIVATIVES - Disclosed are compounds of formulae (I), (II), and (II)I: and pharmaceutically acceptable salts thereof, wherein the variables, R, R | 09-05-2013 |
20130230577 | SLOW-RELEASE FORMULATIONS OF 5-HYDROXYTRYPTOPHAN AS AN ADJUNCT TO PRO-SEROTONERGIC THERAPIES - The present invention concerns the treatment of serotonergic dysregulation disorders and/or augmentation of serotonin levels in the brain by add-on treatments to serotonin enhancers, and slow-release formulations of 5-hydroxytryptophan (5-HTP) therefor. | 09-05-2013 |
20130227720 | Rationally Designed Meganucleases With Altered Sequence Specificity and DNA-Binding Affinity - Rationally-designed LAGLIDADG meganucleases and methods of making such meganucleases are provided. In addition, methods are provided for using the meganucleases to generate recombinant cells and organisms having a desired DNA sequence inserted into a limited number of loci within the genome, as well as methods of gene therapy, for treatment of pathogenic infections, and for in vitro applications in diagnostics and research. | 08-29-2013 |
20130218239 | NON-REGULAR ELECTRICAL STIMULATION PATTERNS FOR TREATING NEUROLOGICAL DISORDERS - Systems and methods for stimulation of neurological tissue and generation stimulation trains with temporal patterns of stimulation, in which the interval between electrical pulses (the inter-pulse intervals) changes or varies over time. The features of the stimulation trains may be selected and arranged algorithmically to by clinical trial. These stimulation trains are generated to target a specific neurological disorder, by arranging sets of features which reduce symptoms of that neurological disorder into a pattern which is effective at reducing those symptoms while maintaining or reducing power consumption versus regular stimulation signals. Compared to conventional continuous, high rate pulse trains having regular (i.e., constant) inter-pulse intervals, the non-regular (i.e., not constant) pulse patterns or trains that embody features of the invention provide increased efficacy and/or a lower than average frequency. | 08-22-2013 |
20130217002 | HIV-1 IGG3 RESPONSE IN ACUTE HIV-1 - The present invention relates, in general, to HIV-1 and, in particular, to methods of detecting incident HIV-1 infection. | 08-22-2013 |
20130210903 | APTAMERS TO GLYCOPROTEIN VI - The present invention relates, in general, to glycoprotein VI (GPVI) and, in particular, to aptamers to GPVI and to compositions comprising same. The invention also relates to methods of inhibiting platelet aggregation using an aptamer that binds to and inhibits the activity of GPVI. The invention further relates to antidotes to GPVI aptamers and to methods of using such antidotes to reverse aptamer-induced platelet inhibition. The invention also relates to aptamers that bind to and enhance the activity of GPVI. | 08-15-2013 |
20130210793 | PHOTOLABILE CAGED TRANSITION METAL COMPLEXES AND METHODS OF USING THE SAME - The present invention provides compounds of Formula I: | 08-15-2013 |
20130210783 | NEUROACTIVE STEROID COMPOSITIONS AND METHODS OF USE THEREFOR - Provided are methods for ameliorating a symptom of a neuropsychiatric disorder. Also provided are methods for ameliorating at least one symptom resulting from tobacco cessation; and for ameliorating a symptom of Alzheimer's disease or other cognitive disorder; of schizophrenia, schizoaffective disorder, or other psychotic disorder; of a depressive disorder; of bipolar disorder; of post-traumatic stress disorder or other anxiety disorder; of a pain disorder; or of traumatic brain injury. Also provided are methods for ameliorating a sleep disorder; for improving cognitive functioning; for predicting a predisposition to suicide, suicidal ideation, and/or suicidal behavior; and for ameliorating a neurodegenerative disorder. In some embodiments, the methods include administering to a subject in need thereof an effective amount of a neuroactive steroid composition, pharmaceutically acceptable salts thereof, derivatives thereof, or combinations thereof. | 08-15-2013 |
20130210136 | Methods For Treating Cardio Pulmonary Diseases With NO Group Compounds - Treatment of pulmonary disorders associated with hypoxemia and/or smooth muscle constriction and/or inflammation comprises administering into the lungs as a gas a compound with an NO group which does not form NO | 08-15-2013 |
20130208969 | SYSTEMS AND METHODS FOR AUTOMATED MAGNETIC RESONANCE IMAGING - Disclosed herein are systems and methods for automated MRI. According to an aspect, a method for MRI includes receiving a plurality of MRI data signals representative of a region including a volume of interest. The method also includes determining at least one subvolume within the VOI. Further, the method includes determining a state of the at least one subvolume. The method also includes implementing a predetermined action based on the predetermined state. | 08-15-2013 |
20130196342 | Compositions And Methods For Modulating S-Nitrosogluthione Reductase - Disclosed herein are methods and compositions for modulating the levels and/or activity of S-nitrosoglutathione reductase (GSNOR) in vivo or in vitro. Specifically disclosed are GSNOR deletion constructs, host cells and non-human mammals comprising GSNOR deletions, and methods of screening employing GSNOR deletion mutants. Also specifically disclosed are reagents and procedures for measuring, monitoring, or altering GSNOR levels or activity (as well as nitric oxide and S-nitrosothiol levels) in connection with various medical conditions. | 08-01-2013 |
20130195834 | TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE II - Methods of treating glycogen storage disease type II, by administering acid α-glucosidase, are described, as are compositions for use in treatment of glycogen storage disease type II. | 08-01-2013 |
20130191935 | METHOD OF REGULATING GENE EXPRESSION - The present invention relates, in general, to gene expression and, in particular, to a method of inhibiting the expression of a target gene and to constructs suitable for use in such a method. | 07-25-2013 |
20130189224 | COMPOSITIONS, METHODS, AND KITS FOR ELICITING AN IMMUNE RESPONSE - The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided. | 07-25-2013 |
20130182932 | Multi-Dimensional Iterative Phase-Cycled Reconstruction For MRI Images - Methods, systems, computer programs, circuits and workstations are configured to carry out image processing to generate MRI images with reduced aliasing artifacts (e.g., Nyquist and/or motion-induced image artifacts) by (a) electronically reconstructing a series of images using patient image data obtained from a patient MRI image data set by iteratively cycling through different estimated values of phase gradients in at least two dimensions; and (b) electronically selecting an image from the reconstructed images as having a lowest artifact level. | 07-18-2013 |
20130178520 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS - Described herein are methods of treating Parkinson's disease using arylcyclopropylamine compounds. | 07-11-2013 |
20130178411 | THERAPEUTIC AGENTS COMPRISING ELASTIC PEPTIDES - The present invention provides therapeutic agents and compositions comprising elastic peptides and therapeutic proteins. Such peptides exhibit a flexible, extended conformation. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist (e.g., GLP-1, exendin), insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability. | 07-11-2013 |
20130177583 | MOLECULAR CLONE OF HIV-1 - The present invention relates, in general, to HIV-1 and, in particular, to a molecular clone of HIV-1. The invention further relates to methods of inducing an immune response to HIV-1 in a patient and to immunogens suitable for use in such methods. The invention also relates to anti-HIV-1 antibodies and to methods of using same to prevent or treat HIV-infection. | 07-11-2013 |
20130177576 | Compositions And Methods For The Treatment Of Neurologic And Psychiatric Conditions - The invention provides pharmaceutical compositions and methods of use thereof for preventing or ameliorating disorders of the nervous system. More specifically, the invention provides pharmaceutical compositions, including phosphopeptides, that when administered disrupt TrkB-mediated activation of PLCγ1 phosphorylation. The invention further provides method of treatment comprising administering inhibitors of TrkB-mediated activation of PLCγ1 phosphorylation alone or in combination with other pharmaceutical compositions to prevent or ameliorate nervous system disorders such as epilepsy, stroke, anxiety, migraine, and pain. | 07-11-2013 |
20130176560 | DUAL WINDOW PROCESSING SCHEMES FOR SPECTROSCOPIC OPTICAL COHERENCE TOMOGRAPHY (OCT) AND FOURIER DOMAIN LOW COHERENCE INTERFEROMETRY - Current apparatuses and methods for analysis of spectroscopic optical coherence tomography (SOCT) signals suffer from an inherent tradeoff between time (depth) and frequency (wavelength) resolution. In one non-limiting embodiment, multiple or dual window (DW) apparatuses and methods for reconstructing time-frequency distributions (TFDs) that applies two windows that independently determine the optical and temporal resolution is provided. For example, optical resolution may relate to scattering information about a sample, and temporal resolution may be related to absorption or depth related information. The effectiveness of the apparatuses and methods is demonstrated in simulations and in processing of measured OCT signals that contain fields which vary in time and frequency. The DW technique may yield TFDs that maintain high spectral and temporal resolution and are free from the artifacts and limitations commonly observed with other processing methods. | 07-11-2013 |
20130172274 | METHODS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS WITH ENHANCED PHARMACOLOGICAL PROPERTIES - Provided herein are methods of enhancing in vivo efficacy of an active agent, comprising: administering to a subject an active agent that is coupled to a bioelastic polymer or elastin-like peptide, wherein the in vivo efficacy of the active agent is enhanced as compared to the same active agent when administered to the subject not coupled to (or not associated with) a bioelastic polymer or ELP. | 07-04-2013 |
20130164742 | Droplet-Based Pyrosequencing - The present invention relates to droplet-based pyrosequencing including a method of identifying a base at a target position in a sample nucleic acid. The method includes: (a) providing a droplet microactuator including a first droplet including a sample nucleic acid immobilized on a bead; and (b) on the droplet microactuator: (i) contacting the first droplet with one or more reagent droplets to yield a second droplet, wherein the one or more reagent droplets include reagents for extending a double stranded portion of the sample nucleic acid by incorporating a nucleotide at the target position; (ii) splitting the second droplet to yield a third droplet including the bead and a fourth droplet lacking the bead; and (iii) assaying the third droplet to determine whether the nucleotide was incorporated at the target position. | 06-27-2013 |
20130164316 | GENETIC SIGNATURES IN HIV-1 SUBTYPE C ENVELOPE GLYCOPROTEINS - The present invention relates, in general, to HIV-1 and, in particular, to immunogens that elicit broadly neutralizing antibodies against HIV-1 subtype C envelope glycoproteins, and compositions comprising same. The invention further relates to methods of inducing the production of such antibodies in a subject. | 06-27-2013 |
20130157889 | DETECTION DEVICES AND RELATED METHODS OF USE - Disclosed are devices and methods for detecting analytes from a sample. | 06-20-2013 |
20130146455 | Droplet Manipulation Device - Methods are provided for manipulating droplets. The methods include providing the droplet on a surface comprising an array of electrodes and a substantially co-planer array of reference elements, wherein the droplet is disposed on a first one of the electrodes, and the droplet at least partially overlaps a second one of the electrodes and an intervening one of the reference elements disposed between the first and second electrodes. The methods further include activating the first and second electrodes to spread at least a portion of the droplet across the second electrode and deactivating the first electrode to move the droplet from the first electrode to the second electrode. | 06-13-2013 |
20130143771 | NON-FOULING POLYMERIC SURFACE MODIFICATION AND SIGNAL AMPLIFICATION METHOD FOR BIOMOLECULAR DETECTION - An article such as a biosensor having a nonfouling surface thereon is described. The article comprises: (a) a substrate having a surface portion; (b) a linking layer on the surface portion; (c) a polymer layer comprising brush molecules formed on the linking layer; and (d) optionally but preferably, a first member of a specific binding pair (e.g., a protein, peptide, antibody, nucleic acid, etc.) coupled to the brush molecules. The polymer layer is preferably formed by the process of surface-initiated polymerization (SIP) of monomeric units thereon. Preferably, each of the monomeric units comprises a monomer (for example, a vinyl monomer) core group having at least one protein-resistant head group coupled thereto, to thereby form the brush molecule on the surface portion. Methods of using the articles are also described. | 06-06-2013 |
20130128264 | SINGLE-MODE OPTICAL FIBER-BASED ANGLE-RESOLVED LOW COHERENCE INTERFEROMETRIC (LCI)(A/LCI) AND NON-INTERFEROMETRIC SYSTEMS AND METHODS - Optical fiber-based angle-resolved low coherence interferometric systems and methods are disclosed for imaging of scattering samples and measurement of optical and structural properties. A single-mode collection optical fiber can be employed and scanned to collect an angular scattering distribution of scattered light from the sample. Use of a single-mode collection optical fiber can reduce cost, increase signal accuracy, and provide compatibility with optical coherence tomography systems, as examples. In certain embodiments, collected angular scatterings of light from the sample are cross-correlated with a reference signal to provide an angular scattering distribution of scattering of light from the sample. The angular scattering distribution can be spectrally dispersed to yield an angle-resolved, spectrally-resolved cross-correlation profile having depth-resolved information about the sample at the scattering angles. The angle-resolved, spectrally-resolved cross-correlation profile can be analyzed to provide size and/or depth information about the sample. The systems and methods can also be employed in non-interferometric modes. | 05-23-2013 |
20130118901 | Apparatuses and Methods for Manipulating Droplets - Apparatuses and methods for manipulating droplets are disclosed. In one embodiment, an apparatus for manipulating droplets is provided, the apparatus including a substrate, multiple arrays of electrodes disposed on the substrate, wherein corresponding electrodes in each array are connected to a common electrical signal, and a dielectric layer disposed on the substrate first side surface and patterned to cover the electrodes. | 05-16-2013 |
20130109971 | METHODS, SYSTEMS AND APPARATUSES FOR VAN-CITTERT ZERNIKE IMAGING | 05-02-2013 |
20130100439 | SMART FIBER OPTIC SENSORS SYSTEMS AND METHODS FOR QUANTITATIVE OPTICAL SPECTROSCOPY - Smart fiber optic sensors, systems, and methods for performing quantitative optical spectroscopy are disclosed. In one embodiment, smart fiber optic sensor can include a sensing channel, a calibration channel, and a pressure sensing channel. External force or pressure can be calculated at pressure sensing channel for monitoring and controlling pressure at a sensor-specimen interface thereby ensuring more accurate specimen spectral data is collected. Contact pressure can be adjusted to remain within a specified range. A calibration light of the calibration channel and an illumination light of the sensing channel can be generated simultaneously from a shared light source. Pressure sensing channel can transmit light from a second light source and collect pressure spectral data. | 04-25-2013 |
20130092539 | DROPLET-BASED NUCLEIC ACID AMPLIFICATION METHOD AND APPARATUS - Aspects of embodiments of the invention relate to a simulator including a visual display capable of outputting to a user a display one or more effects of a command series selected and a system including a droplet microactuator electronically coupled to and controlled by a processor capable of executing instructions, the droplet microactuator including a substrate comprising electrodes for conducting droplet operations. Further aspects of embodiments of the invention relate to a droplet operations troubleshooting apparatus. Other aspects of embodiments of the invention relate to a computer implemented method of displaying simulated microactuator droplets. | 04-18-2013 |
20130089869 | Methods For and Uses of Mechanical Stiffness Profiling of Cancer Cells - Methods of predicting the invasiveness or metastatic potential of cancer cells are provided herein. Methods of screening for cancer cells or diagnosing cancer in a subject are also provided. Methods of screening for agents capable of reducing invasiveness or metastasis of cancer cells are also provided. All of the methods rely on analyzing the creep compliance or spring constant of cells. | 04-11-2013 |
20130085104 | THERAPEUTIC AGENTS COMPRISING ELASTIN-LIKE PEPTIDES - The present invention provides therapeutic agents and compositions comprising elastin-like peptides (ELPs) and therapeutic proteins. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist, insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability. | 04-04-2013 |
20130085099 | THERAPEUTIC AGENTS COMPRISING ELASTIN-LIKE PEPTIDES - The present invention provides therapeutic agents and compositions comprising elastin-like peptides (ELPs) and therapeutic proteins. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist, insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistence in the body, solubility, and bioavailability. | 04-04-2013 |
20130084294 | ANTI-CD19 ANTIBODIES AND USES IN B CELL DISORDERS - The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies and autoimmune diseases and disorders, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies. | 04-04-2013 |
20130079277 | THERAPEUTIC AGENTS COMPRISING ELASTIN-LIKE PEPTIDES - The present invention provides therapeutic agents and compositions comprising elastin-like peptides (ELPs) and therapeutic proteins. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist, insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability. | 03-28-2013 |
20130063801 | SCANNER APPARATUS HAVING ELECTROMAGNETIC RADIATION DEVICES COUPLED TO MEMS ACTUATORS - A disclosed scanner apparatus includes a member having spaced apart proximal and distal portions. An electromagnetic radiation device is configured to direct electromagnetic radiation therefrom and is moveably coupled to the distal portion of the member. The electromagnetic radiation device is configured to move in a first plane of movement to a first position to direct the electromagnetic radiation along a first path and configured to move in the plane of movement to a second position to direct the electromagnetic radiation along a second path. A MicroElectroMechanical Systems (MEMS) actuator is coupled to the electromagnetic radiation device, wherein the MEMS actuator is configured to move in a first direction to move the electromagnetic radiation device to the first position and configured to move in a second direction to move the electromagnetic radiation device to the second position. Other scanning and robotic structure devices are disclosed. | 03-14-2013 |
20130060005 | COMPOSITIONS AND METHODS FOR INHIBITING THE INTERACTION BETWEEN CFTR AND CAL - The present invention features compositions and methods for increasing the cell surface expression of degradation-prone CFTR proteins and preventing or treating cystic fibrosis. The invention provides peptides and peptidomimetics that selectively inhibit the interaction between CAL and mutant CFTR proteins, thereby stabilizing the CFTR and facilitating transport of the same to the cell surface. | 03-07-2013 |
20130059788 | PRODOMAIN MODULATORS OF ADAM 10 - The presently disclosed subject matter discloses isolated ADAM 10 modulating peptides and related compounds useful for studying the biological functions of ADAM 10 and for the treatment of diseases such as cancer, neurological disorders, asthma, and allergic responses, and disorders characterized at least in part by the presence of one or more of inflammation, excess cell proliferation, angiogenesis, and excess soluble CD23. In one aspect, the presently disclosed subject matter provides isolated mouse and human ADAM 10 prodomain comprising the sequence set forth in SEQ ID NOs 1-8, or a sequence having at least 95% homology to any of SEQ ID NOs 1-8 and having the functionality of modulating ADAM 10 activity. | 03-07-2013 |
20130059366 | Integrated Droplet Actuator for Gel; Electrophoresis and Molecular Analysis - The invention is directed to a droplet actuator device and methods for integrating gel electrophoresis analysis with pre or post-analytical sample handling as well as other molecular analysis processes. Using digital microfluidics technology, the droplet actuator device and methods of the invention provide the ability to perform gel electrophoresis and liquid handling operations on a single integrated device. The integrated liquid handling operations may be used to prepare and deliver samples to the electrophoresis gel, capture and subsequently process products of the electrophoresis gel or perform additional assays on the same sample materials which are analyzed by gel electrophoresis. In one embodiment, one or more molecular assays, such as nucleic acid (e.g., DNA) quantification by real-time PCR, and one or more sample processing operations such as sample dilution is performed on a droplet actuator integrated with an electrophoresis gel. In one embodiment, an electrophoresis gel may be integrated on the top substrate of the droplet actuator. | 03-07-2013 |
20130058909 | METHODS OF TREATMENT USING EX VIVO EXPANSION OF CORD BLOOD T CELLS - Provided are methods of enhancing ex vivo proliferation of a T cell population, the methods comprising contacting the T cell population with IL-7 and anti-CD3/CD28 antibody to activate and expand the T cell population. Further provided are methods of generating an antigen-specific cytotoxic T cell population comprising priming a CD3/CD28-expanded T cell population against an antigen (e.g., a cancer cell) in the presence of at least one of IL-7, IL-12, and IL-15, or a combination thereof. Further provided are methods of treating T cell lymphopenia in a subject, comprising administering a CD3/CD28-expanded T cell population to the subject. | 03-07-2013 |
20130052677 | PEG-Urate Oxidase Conjugates and Use Thereof - A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme. | 02-28-2013 |
20130046010 | SUMO AS A MARKER OF CANCER DEVELOPMENT AND TARGET FOR CANCER THERAPY - Disclosed herein are methods relating to inhibiting or reducing proliferation of a cancer cell, for treating cancer in a subject in need of treatment, predicting the risk of progression of cancer to a more aggressive cancer, and screening for cancer in a subject, that comprise detecting and/or decreasing the levels of SUMO conjugated proteins and detecting and/or interfering with SUMO conjugation. | 02-21-2013 |
20130023587 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER - Provided are methods for inhibiting survival of a proliferating, quiescent, or hypoxic cancer cell that include administering a compound that inhibits lactate clearance (e.g., lactate catabolism, lactate transport, glutamate release, and/or alanine release) in the proliferating, quiescent, or hypoxic cancer cell. Further provided are methods of reducing the proliferation of a neoplastic cell having increased lactate or decreased glucose concentrations relative to a normal cell. Also provided are methods of treating a subject having cancer, wherein the methods may include administering to the subject an inhibitor of lactate clearance. | 01-24-2013 |
20130022598 | Dual Specific Immunotoxin for Brain Tumor Therapy - We tested the in vitro and in vivo efficacy of a recombinant bispecific immunotoxin that recognizes both EGFRwt and tumor-specific EGFRvIII receptors. A single chain antibody was cloned from a hybridoma and fused to toxin, carrying a C-terminal peptide which increases retention within cells. The binding affinity and specificity of the recombinant bispecific immunotoxin for the EGFRwt and the EGFRvIII proteins was measured. In vitro cytotoxicity was measured. In vivo activity of the recombinant bispecific immunotoxin was evaluated in subcutaneous models and compared to that of an established monospecific immunotoxin. In our preclinical studies, the bispecific recombinant immunotoxin, exhibited significant potential for treating brain tumors. | 01-24-2013 |
20130018001 | METHODS OF DIAGNOSING CANCER - Provided are methods of predicting or assessing the level of severity of cancer or cancer progression in a patient comprising measuring levels of SET expression in a biological sample from a patient and comparing levels of SET expression to a control sample or standard value. Methods for predicting or evaluating the efficacy of a SET therapeutic and kits comprising at least one reagent for measuring SET protein expression are also provided. | 01-17-2013 |
20130017962 | METHODS AND COMPOSITIONS FOR CORRELATING GENETIC MARKERS WITH CARDIOVASCULAR DISEASE - The present invention provides methods of identifying a subject having an increased or decreased risk of developing cardiovascular disease, comprising: a) correlating the presence of one or more genetic markers in chromosome 3q13.31 with an increased or decreased risk of developing cardiovascular disease; and b) detecting the one or more genetic markers of step (a) in the subject, thereby identifying the subject as having an increased or decreased risk of developing cardiovascular disease. Also provided are methods of identifying subjects with cardiovascular disease as having a good or poor prognosis, as well as methods of identifying effective treatment regimens for cardiovascular disease, based on correlation with genetic markers in chromosome 3q13.31. | 01-17-2013 |
20130016943 | OPTICAL ISOLATOR - Various optical isolator embodiments are disclosed. Embodiments comprise a waveguide section utilizing materials that induce a propagation constant shift that is propagation-direction-dependent. Embodiments are characterized by a cutoff frequency for forward propagating waves that is different than the cutoff frequency for reverse waves. A particular embodiment is constructed as a single-mode waveguide on a substrate. The cross-section of the waveguide is inhomogeneous in terms of materials. This inhomogeneity induces a propagation constant shift, which is propagation-direction-dependent. This device works as an optical isolator from the cut-off frequency of the lowest forward wave (lower frequency) to one for the lowest reverse wave (higher frequency). Various configurations consistent with the principles of the invention are disclosed. | 01-17-2013 |
20130008690 | COMPOSITIONS AND METHODS FOR GROWING COPPER NANOWIRES - A method of synthesis to produce gram-scale quantities of copper nanowires in an aqueous solution, wherein the copper nanowires are dispersed in said solution. Copper nanowires grow from spherical copper nanoparticles within the first 5 minutes of the reaction. Copper nanowires can be collected from solution and printed to make conductive films (preferably <10,000 Ω/sq) that preferably transmit greater than 60% of visible light. | 01-10-2013 |
20130006557 | METHOD AND ARCHITECTURE FOR PRE-BOND PROBING OF TSVs IN 3D STACKED INTEGRATED CIRCUITS - On-chip test architecture and design-for-testability methods for pre-bond testing of TSVs are provided. In accordance with certain embodiments of the invention, a die level wrapper is provided including gated scan flops connected to one end of each TSV. The gated scan flops include a scan flop structure and a gated output. The gated output is controlled by a signal to cause the output of the gated scan flop to either be in a “floated state” or take the value stored in the flip-flop portion of the gated scan flop. The gated output of the gated scan flop can be used to enable resistance and capacitance measurements of pre-bonded TSVs. | 01-03-2013 |
20130005664 | THERAPEUTIC AGENTS COMPRISING ELASTIC PEPTIDES - The present invention provides therapeutic agents and compositions comprising elastic peptides and therapeutic proteins. Such peptides exhibit a flexible, extended conformation. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist (e.g., GLP-1, exendin), insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability. | 01-03-2013 |
20120329666 | Peripheral Blood Biomarkers for Idiopathic Interstitial Pneumonia and Methods of Use - The present invention provides methods for diagnosing several types of diseases. Specifically, the present disclosure provides a panel of diagnostic genes, the differential expression of whose mRNAs or proteins in the sample of a subject indicates the presence of the disease in the subject. The methods involve extracting mRNAs or proteins from the sample and performing gene expression profiling assays such as microarray assay, RT-PCR oligonucleotide binding array, quantitative RT-PCR assay, proteomics assay, and/or ELISA assay. | 12-27-2012 |
20120322769 | METHODS OF REDUCING VIRULENCE IN BACTERIA - A method of reducing virulence in a bacterium comprising at least one of a GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS-type system, and a Rsm-type system, the method comprising contacting the bacterium with an effective amount of a compound described herein. | 12-20-2012 |
20120322667 | METHODS OF IDENTIFYING INDIVIDUALS AT RISK OF PERIOPERATIVE BLEEDING, RENAL DYSFUNCTION OR STROKE - The present invention relates, in general, to perioperative bleeding and, in particular, to methods of identifying individuals at risk of perioperative bleeding. | 12-20-2012 |
20120322084 | CELL LINES COMPRISING SOUR-TASTE RECEPTORS - The present invention relates to sour taste receptors and compositions and methods thereof. In particular, the present invention provides assays and methods of screening for ligands specific for sour taste receptors. Additionally, the present invention provides methods for screening for accessory proteins and mutations, polymorphisms and other potential sour taste receptor protein mutations that are associated with disease states, and therapeutic agents, ligands, and modulators of such proteins. The present invention also provides compositions and methods for modulating sour taste receptors in vitro and in vivo. | 12-20-2012 |
20120315654 | COMPOSITIONS AND METHODS FOR DETECTING CARDIOTOXICITY - The present disclosure provides methods and compositions for detecting the presence and activity of creatine transporter proteins (CrT) in biological samples comprising screening the samples for CrT using antibodies that bind to the CrT. The methods are useful to detect the onset of cardiotoxicity in subjects undergoing treatment with anthrocyclines or those susceptible to heart-related conditions. The methods and compositions described herein in can be practiced with diagnostic kits. | 12-13-2012 |
20120288931 | METHODS FOR TREATING CANCERS AND PATHOGEN INFECTIONS USING ANTIGEN-PRESENTING CELLS LOADED WITH RNA - Disclosed are cells and methods for treating or preventing tumor formation or infections with pathogens in a patient. The cells of the invention are antigen-presenting cells (e.g., dendritic cells or macrophage) that have been loaded with RNA derived from tumors or pathogens. By administering the RNA-loaded antigen-presenting cells to a patient, tumor formation or pathogen infections can be treated or prevented. Alternatively, the RNA-loaded cells can be used as stimulator cells in the ex vivo expansion of CTL. Such CTL can then be used in a variation of conventional adoptive immunotherapy techniques. | 11-15-2012 |
20120286897 | METAMATERIAL WAVEGUIDE LENS - A metamaterial waveguide structure is disclosed. In some approaches the metamaterial waveguide structure is compressed along an optical axis using transformation optics techniques. An example is a Rotman lens that is compressed by 27 percent along the optical axis while maintaining the beam steering range, gain and side lobe amplitudes over a broad frequency range. In some approaches the metamaterial waveguide structure includes a plurality of complementary metamaterial elements patterned on a conducting surface of the waveguide. | 11-15-2012 |
20120281224 | SYSTEMS AND METHODS FOR ENDOSCOPIC ANGLE-RESOLVED LOW COHERENCE INTERFEROMETRY - Fourier domain a/LCI (faLCI) system and method which enables in vivo data acquisition at rapid rates using a single scan. Angle-resolved and depth resolved spectra information is obtained with one scan. The reference arm can remain fixed with respect to the sample due to only one scan required. A reference signal and a reflected sample signal are cross-correlated and dispersed at a multitude of reflected angles off of the sample, thereby representing reflections from a multitude of points on the sample at the same time in parallel. Information about all depths of the sample at each of the multitude of different points on the sample can be obtained with one scan on the order of approximately 40 milliseconds. From the spatial, cross-correlated reference signal, structural (size) information can also be obtained using techniques that allow size information of scatterers to be obtained from angle-resolved data. | 11-08-2012 |
20120276072 | CONSTRUCTS FOR EXPRESSING LYSOSOMAL POLYPEPTIDES - Provided are isolated nucleic acids for expressing lysosomal polypeptides such as lysosomal acid α-glucosidase (GAA) and vectors comprising the same. The invention provides an isolated nucleic acid encoding a chimeric polypeptide comprising a secretory signal sequence operably linked to a lysosomal polypeptide. The invention also provides an isolated nucleic acid comprising a coding region encoding a GAA and a GAA 3′ untranslated region (UTR), wherein the GAA 3′ UTR comprises a deletion therein. The invention further provides an isolated nucleic acid comprising a coding region encoding a GAA and a 3′ UTR wherein the 3′ UTR is less than about 200 nucleotides in length and comprises a segment that is heterologous to the GAA coding region. Also provided are methods of making and using delivery vectors encoding lysosomal polypeptides to produce the lysosomal polypeptide to treat subjects afflicted with a deficiency in the lysosomal polypeptide. | 11-01-2012 |
20120270812 | COMPOSITIONS, METHODS, AND KITS FOR DETERMINING AN ALKYL TRANSFERASE - The present invention relates to novel compounds as well as to compositions, methods, and kits comprising the compounds for determining an alkyltransferase (ATase), in particular an alkylguanine-DNA alkyl transferase (AGT). In general, the novel compounds provide for determining ATase levels, in particular for in vivo applications including, but not limited to, theranostic applications, in particular to cancer-related applications. | 10-25-2012 |
20120270790 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MYOCARDIAL ISCHEMIA/REPERFUSION INJURY WITH ANNEXIN A1 SHORT PEPTIDE - The present invention provides a method of treating, ameliorating or preventing myocardial ischemia/reperfusion injury in a subject in need thereof, by administering to the subject a therapeutically effective amount of an ANXA1short peptide (ANXA1sp). | 10-25-2012 |
20120266266 | METHODS OF PRODUCING GENETICALLY-MODIFIED EUKARYOTIC CELLS WITH RATIONALLY-DESIGNED MEGANUCLEASES - Rationally-designed LAGLIDADG meganucleases and methods of making such meganucleases are provided. In addition, methods are provided for using the meganucleases to generate recombinant cells and organisms having a desired DNA sequence inserted into a limited number of loci within the genome, as well as methods of gene therapy, for treatment of pathogenic infections, and for in vitro applications in diagnostics and research. | 10-18-2012 |
20120264815 | REVERSIBLE PLATELET INHIBITION - The present invention relates, in general, to receptors and to platelet aggregation and, in particular, to a method of inhibiting platelet aggregation using an aptamer that binds to and inhibits the activity of a receptor, such as glycoprotein IIb/IIIa (gpIIb/IIIa), and to aptamers suitable for use in such a method. The invention also relates to antidotes to antiplatelet agents and to methods of using such antidotes to reverse aptamer-induced platelet inhibition. The invention further relates to von Willebrand Factor (VWF) inhibitors, and antidotes therefore, and to methods of using same. | 10-18-2012 |
20120264136 | METHODS OF DETECTING CHARCOT-MARIE TOOTH DISEASE TYPE 2A - Methods are described for screening a subject for risk of Charcot-Marie-Tooth Disease Type 2A or for diagnosing Charcot-Marie-Tooth disease or a predisposition for developing Charcot-Marie-Tooth disease in a subject, by detecting the presence or absence of a mutation in the mitofusin gene in a biological sample collected from the subject. Methods are also described for detecting the presence of a genetic polymorphism associated with Charcot-Marie-Tooth Disease Type 2A in a sample of patient nucleic acid, by amplifying a mitofusin gene sequence in the patient nucleic acid to produce an amplification product; and identifying the presence of a Charcot-Marie-Tooth Disease Type 2A associated polymorphism in the amplification product. | 10-18-2012 |
20120255042 | METHOD OF REGULATING GENE EXPRESSION - The present invention relates, in general, to gene expression and, in particular, to a method of inhibiting the expression of a target gene and to constructs suitable for use in such a method. | 10-04-2012 |